Biotech IPO buzz, pharma deal trends, Washington update — a BioCentury podcast

Three’s the charm as another IPO enters the queue

Shaking up an underwhelming year for fresh biotech paper, a trio of biotechs filed to go public on NASDAQ last week. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the IPO filings by MBX Biosciences Inc. and Massachusetts companies Zenas BioPharma Inc. and  Bicara Therapeutics Inc.

Washington Editor Steve Usdin returns to the podcast to provide updates on the Inflation Reduction and Biosecure acts, as well as the life sciences policies of presidential candidates Donald Trump and Kamala Harris. 

And Director of Biopharma Intelligence Karen Tkach Tuzman zeroes in on the latest trends among pharma’s deals with biotechs over the past 12 months and the newest start-up out of Versant Ventures, Borealis Biosciences Inc.